FKBP5 and metabolic dysfunction-associated steatotic liver disease: This technology has been used to silence genes crucial for adipocyte differentiation, such as PPARG and FKBP5 [53], as well as to target three genes (SOCS3, DUSP1, and SIK1) that are upregulated in the adipose tissue of patients with nonalcoholic fatty liver disease (NAFLD) [54].